Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre …
M Bocchia, S Gentili, E Abruzzese, A Fanelli, F Iuliano… - The Lancet, 2005 - thelancet.com
Background Although imatinib is the standard treatment for chronic myeloid leukaemia, not
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre …
M Bocchia, S Gentili, E Abruzzese, A Fanelli… - Lancet (London …, 2005 - europepmc.org
Background Although imatinib is the standard treatment for chronic myeloid leukaemia, not
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …
[引用][C] Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a …
M Bocchia, S Gentili, E Abruzzese, A Fanelli, F Iuliano… - The Lancet, 2005 - cir.nii.ac.jp
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with
chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial …
chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial …
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre …
M Bocchia, S Gentili, E Abruzzese, A Fanelli, F Iuliano… - The Lancet, 2005 - infona.pl
Although imatinib is the standard treatment for chronic myeloid leukaemia, not all patients
reach complete cytogenetic remission (CCR) and most maintain detectable disease at the …
reach complete cytogenetic remission (CCR) and most maintain detectable disease at the …
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre …
M Bocchia, S Gentili, E Abruzzese… - Lancet (London …, 2005 - pubmed.ncbi.nlm.nih.gov
Background Although imatinib is the standard treatment for chronic myeloid leukaemia, not
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …
[PDF][PDF] Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a …
M Bocchia, S Gentili, E Abruzzese, A Fanelli, F Iuliano… - Lancet, 2005 - academia.edu
Background Although imatinib is the standard treatment for chronic myeloid leukaemia, not
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …
[引用][C] Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a …
M BOCCHIA, S GENTILI, S AMADORI… - Lancet (British …, 2005 - pascal-francis.inist.fr
Author BOCCHIA, M 1; GENTILI, S 1; AMADORI, S 2; LAURIA, F 1; WONG, K. K
(Commentator) 6; CHATTERJEE, Saswati (Commentator) 7; ABRUZZESE, E 2; FANELLI, A …
(Commentator) 6; CHATTERJEE, Saswati (Commentator) 7; ABRUZZESE, E 2; FANELLI, A …
[PDF][PDF] Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a …
M Bocchia, S Gentili, E Abruzzese, A Fanelli, F Iuliano… - Lancet, 2005 - core.ac.uk
Background Although imatinib is the standard treatment for chronic myeloid leukaemia, not
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre …
M Bocchia, S Gentili, E Abruzzese, A Fanelli… - THE …, 2005 - usiena-air.unisi.it
Although imatinib is the standard treatment for chronic myeloid leukaemia, not all patients
reach complete cytogenetic remission (CCR) and most maintain detectable disease at the …
reach complete cytogenetic remission (CCR) and most maintain detectable disease at the …
[引用][C] Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a …
M Bocchia, S Gentili, E Abruzzese, A Fanelli, F Iuliano… - Lancet, 2005 - eprints.soton.ac.uk
Addition of CMLVAX100 to conventional treatment in patients with chronic myeloid
leukaemia might favour further reduction of residual disease and increase the number of …
leukaemia might favour further reduction of residual disease and increase the number of …